

OV - Ovarian serous cystadenocarcinoma

Subtype	Biology & Expression	Genomic Alterations	Clinical Features
Differentiated	High expression of epithelial and secretory markers (MUC16, MUC1, FOXA2); moderate stromal signals	Enrichment for wild-type CCNE1; frequent BRCA1/2 methylation	Relatively longer overall survival; often platinum-sensitive
Immunoreactive	Upregulation of immune signaling (CXCL9/10, CD3, HLA genes); high T-cell and NK cell infiltration	Similar TP53 ubiquity; occasional BRCA1/2 mutations	Better response to immunotherapy in trials; intermediate prognosis
Mesenchymal	Strong stromal and EMT signatures (COL1A1, VIM, FN1); TGF- β pathway activation	Higher frequency of NF1 and PTEN alterations	Poorer prognosis; more desmoplastic stroma; often chemoresistant
Proliferative	Elevated cell-cycle and DNA replication programs (MKI67, E2F targets, G2M checkpoint)	Enriched CCNE1 and MYC amplifications; low BRCA1/2 involvement	Worst overall survival; high tumor grade; early relapse after platinum therapy